Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
$0.01
$0.06
$0.33
N/AN/A34,287 shsN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.05
N/A-2.5616,027 shsN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$4.26
-10.5%
$6.52
$4.11
$25.00
N/AN/A65,138 shs17,554 shs
Tricida, Inc. stock logo
TCDAQ
Tricida
$0.01
$0.01
$13.85
N/AN/AN/AN/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
0.00%+40.85%-24.76%-52.61%-72.30%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%-95.00%-83.33%0.00%-99.20%
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
-10.50%-24.06%-40.67%+425,999,900.00%+425,999,900.00%
Tricida, Inc. stock logo
TCDAQ
Tricida
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.6034 of 5 stars
0.01.00.04.50.60.00.0
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
0.00
N/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
$79.99KN/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/A0.00N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest TCDAQ, AEHAW, CALA, and NTHI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/A-$2.10N/A-$2.10N/A$0.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Neonc Technologies Holdings, Inc. stock logo
NTHI
Neonc Technologies
8N/AN/AN/A
Tricida, Inc. stock logo
TCDAQ
Tricida
N/AN/AN/AOptionable

Recent News About These Companies

Chronic Kidney Disease News
Brian C. Murray
BAF Viet Nam Agriculture JSC (BAF)
RattanIndia Power Ltd (RTNP)
Tofas Turk Otomobil Fabrikasi AS (TOASO)
Mag Silver (NYSEMKT: MAG)
Tricida, Inc. (TCDAQ)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.01 0.00 (0.00%)
As of 06/18/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Neonc Technologies stock logo

Neonc Technologies NASDAQ:NTHI

$4.26 -0.50 (-10.50%)
As of 06/20/2025 04:00 PM Eastern

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Tricida stock logo

Tricida NASDAQ:TCDAQ

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.